Baker Bros. Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-324,630
| Closed | -$15.4M | – | 89 |
|
|
2025
Q3 | $15.4M | Hold |
324,630
| – | – | 0.11% | 52 |
|
|
2025
Q2 | $17.3M | Sell |
324,630
-224,083
| -41% | -$10.2M | 0.17% | 42 |
|
|
2025
Q1 | $22.2M | Sell |
548,713
-548,369
| -50% | -$23.2M | 0.25% | 34 |
|
|
2024
Q4 | $30.5M | Hold |
1,097,082
| – | – | 0.33% | 33 |
|
|
2024
Q3 | $31.5M | Hold |
1,097,082
| – | – | 0.33% | 34 |
|
|
2024
Q2 | $25.7M | Sell |
1,097,082
-1,616,123
| -60% | -$34.6M | 0.33% | 37 |
|
|
2024
Q1 | $68.5M | Buy |
2,713,205
+344,827
| +15% | +$8.28M | 0.86% | 17 |
|
|
2023
Q4 | $55.3M | Hold |
2,368,378
| – | – | 0.63% | 21 |
|
|
2023
Q3 | $120M | Hold |
2,368,378
| – | – | 0.69% | 11 |
|
|
2023
Q2 | $111M | Hold |
2,368,378
| – | – | 0.64% | 10 |
|
|
2023
Q1 | $90.6M | Hold |
2,368,378
| – | – | 0.49% | 12 |
|
|
2022
Q4 | $130M | Hold |
2,368,378
| – | – | 0.78% | 11 |
|
|
2022
Q3 | $80.6M | Buy |
2,368,378
+2,250,000
| +1,901% | +$34.4M | 0.53% | 18 |
|
|
2022
Q2 | $1.12M | Hold |
118,378
| – | – | 0.01% | 100 |
|
|
2022
Q1 | $1.68M | Hold |
118,378
| – | – | 0.01% | 103 |
|
|
2021
Q4 | $2.5M | Hold |
118,378
| – | – | 0.01% | 102 |
|
|
2021
Q3 | $2.65M | Hold |
118,378
| – | – | 0.01% | 106 |
|
|
2021
Q2 | $2.94M | Hold |
118,378
| – | – | 0.01% | 105 |
|
|
2021
Q1 | $3.43M | Hold |
118,378
| – | – | 0.01% | 104 |
|
|
2020
Q4 | $3.05M | Sell |
118,378
-13,410
| -10% | -$373K | 0.01% | 105 |
|
|
2020
Q3 | $4.06M | Buy |
+131,788
| New | +$4.61M | 0.02% | 85 |
|
Other funds holding AKRO
Baker Bros. Advisors's AKRO Position: Q4 2025 in Review
Baker Bros. Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 324,630 shares — an estimated $15.4M sold.
Baker Bros. Advisors first reported a position in AKRO in Q3 2020 and held it in 21 quarters. The position peaked at $130M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Baker Bros. Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Baker Bros. Advisors sold 324,630 Akero Therapeutics shares in Q4 2025, an estimated $15.4M.
- Baker Bros. Advisors first reported a position in Akero Therapeutics in Q3 2020 and held it in 21 quarters.
- Baker Bros. Advisors's Akero Therapeutics position peaked at $130M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.